CN112522312B - WKH rat model construction method - Google Patents
WKH rat model construction method Download PDFInfo
- Publication number
- CN112522312B CN112522312B CN202011326345.8A CN202011326345A CN112522312B CN 112522312 B CN112522312 B CN 112522312B CN 202011326345 A CN202011326345 A CN 202011326345A CN 112522312 B CN112522312 B CN 112522312B
- Authority
- CN
- China
- Prior art keywords
- cacna1d
- rat
- rats
- wkh
- rat model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011552 rat model Methods 0.000 title claims abstract description 33
- 238000010276 construction Methods 0.000 title claims description 12
- 108091033409 CRISPR Proteins 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 6
- 238000012163 sequencing technique Methods 0.000 claims abstract description 4
- 241000700159 Rattus Species 0.000 claims description 68
- 230000035772 mutation Effects 0.000 claims description 19
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 14
- 108700024394 Exon Proteins 0.000 claims description 11
- 241000699670 Mus sp. Species 0.000 claims description 11
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 108020005004 Guide RNA Proteins 0.000 claims description 9
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims description 6
- 235000013601 eggs Nutrition 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 101100058876 Rattus norvegicus Cacna1d gene Proteins 0.000 claims description 4
- 101150038500 cas9 gene Proteins 0.000 claims description 4
- 230000037432 silent mutation Effects 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 108091081024 Start codon Proteins 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 238000013461 design Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000003198 gene knock in Methods 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 101100046145 Rattus norvegicus F2 gene Proteins 0.000 claims 1
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 48
- 108090000623 proteins and genes Proteins 0.000 abstract description 30
- 241001465754 Metazoa Species 0.000 abstract description 15
- 230000036772 blood pressure Effects 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 8
- 230000008506 pathogenesis Effects 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 3
- 230000035488 systolic blood pressure Effects 0.000 abstract description 3
- 108091026890 Coding region Proteins 0.000 abstract description 2
- 230000002776 aggregation Effects 0.000 abstract description 2
- 238000004220 aggregation Methods 0.000 abstract description 2
- 230000007918 pathogenicity Effects 0.000 abstract description 2
- 101000867817 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1D Proteins 0.000 description 23
- 102000014816 CACNA1D Human genes 0.000 description 17
- 230000008859 change Effects 0.000 description 9
- 230000001631 hypertensive effect Effects 0.000 description 8
- 101000836074 Mus musculus Prostatic spermine-binding protein Proteins 0.000 description 5
- 101000703431 Mus musculus Sex hormone-binding globulin Proteins 0.000 description 5
- 101150025500 CACNA1D gene Proteins 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 4
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 4
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 102100033902 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102100032575 Voltage-dependent L-type calcium channel subunit alpha-1D Human genes 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 208000015345 genetic hypertension Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000009404 close breeding Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 102000053844 human CACNA1D Human genes 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of a method for constructing a hereditary hypertension rat model, in particular to a method for constructing a WKH rat model, which comprises the following steps: adopting gene sequencing technology to detect coding regions and flanking regions of 43 pathogenic genes related to single-gene hypertension of clinical teenager hypertension patients with familial aggregation, predicting the influence of newly-discovered mutant genes on protein structure and function through a plurality of software, and determining the pathogenic genes through pathogenicity judgment; then, the WKH rat model is constructed by utilizing a gene engineering CRISPR/Cas9 technology, the postnatal blood pressure of the mutant gene animal is continuously increased along with the age of the animal, and the systolic pressure of most offspring tail animals is more than 140mmHg. Provides a research tool for the function of the gene in the development of hypertension, and provides a research model for continuously exploring the pathogenesis related to hypertension and exploring a new target point of the antihypertensive effect.
Description
Technical Field
The invention relates to the technical field of a method for constructing a hereditary hypertension rat model, in particular to a method for constructing a WKH rat model, namely a method for constructing a humanized hereditary hypertension rat model.
Background
With the improvement of living standard of people, the life of people is continuously increased, the prevalence rate of hypertension in China is also continuously increased, and the guideline of the prevention and treatment of hypertension in China in 2019 shows that the total number of people suffering from hypertension in China is about 2 hundred million, namely, 2 hypertension patients exist in 10 adults, as the cardiovascular and cerebrovascular diseases are the leading cause of death and disability in China, the hypertension is also the first risk factor of cardiovascular and cerebrovascular diseases, therefore, the control of the blood pressure level of people is very important, but the current situation is that the treatment control rate of the hypertension patients in China is only 16%, one of the causes is related to the complication and complication of the pathogenesis of hypertension, and a plurality of problems of genetic factors need to be solved urgently.
For the research of human hypertension pathogenesis and prevention and treatment scheme, a genetic hypertension model can be constructed by a genetic method, such as a selective recent propagation hypertension model and a genetic engineering hypertension model. The former model is to perform close breeding of the screened congenital hypertension animal for a plurality of generations (more than 20 generations) to obtain stable hypertension inheritance. Hypertensive rabbits, rats and mice have been developed. Rats are commonly used, and more mature varieties include: spontaneous Hypertensive Rats (SHR), dahl salt-sensitive rats (DS), milan hypertensive rats (MHS), and hereditary hypertensive rats (GH) are also called New Zealand hypertensive rats, israel hypertensive rats (SBH), and Lyon hypertensive rats (LH). Although these models are very similar to human hypertension, the following deficiencies still exist: (1) it is obtained by selective reproduction and is different from human diseases. (2) Abnormalities in thyroid and immune function exist.
Genetically engineered hypertension models can be divided into two categories: one is that a transgenic technology is adopted to randomly integrate exogenous genes into an animal genome and cause hypertension through over expression, and the transgenic animal is called hypertension; the other is that the endogenous gene of the animal is directionally knocked out by adopting a gene targeting technology to cause hypertension, and the animal is called a hypertension gene knockout animal. Because the technology and laboratory requirements for preparing the gene engineering hypertension model are higher, the reports of successfully preparing the gene engineering hypertension model in China are less. With the development of CRISPR-Cas9 technology, a gene manipulation tool, it has recently been widely applied to various experimental models such as cell lines, laboratory animals, plants, and even human clinical trials. The CRISPR-Cas9 system includes a guide Cas9 nuclease, guided by small RNA molecules, creating site-directed double-stranded DNA breaks. A process that allows permanent modification of a genomic target sequence can repair DNA damage. The application of the system is proposed to provide a new approach for treating hypertension and cardiovascular diseases. Therefore, the animal model aims to screen pathogenic genes from hypertension families, a specific genetic variation genetic hypertension rat model (WKH rat model) is constructed by using a CRISPR-Cas9 gene editing technology, and a new tool is provided for screening antihypertensive drugs with specific action targets.
The Cav1.3L-type calcium channel alpha 1 subunit coding gene CACNA1D is related to hypertension, the CACNA1D gene is reported to be a newly found blood pressure susceptible region in literature, chinese scholars find that rs9810888 polymorphism is obviously related to diastolic pressure and average arterial pressure, poor living mode and rs9810888 GG genotype synergy can influence the blood pressure level of Chinese teenagers, and the change of the CACNA1D gene function can influence the blood pressure reduction effect of a calcium channel blocker.
Disclosure of Invention
The invention aims to provide a WKH rat model construction method, which overcomes the defects of the prior art, provides a research tool for the action in the development of hypertension, and provides a research model for continuously exploring the pathogenesis related to hypertension and exploring a new target point of the antihypertensive action.
One of the technical schemes of the invention is realized by the following measures: a WKH rat model construction method comprises the following steps: adopting gene sequencing technology to detect coding regions and flanking regions of 43 pathogenic genes related to single-gene hypertension of clinical teenager hypertension patients with familial aggregation, predicting the influence of newly-discovered mutant genes on protein structure and function through a plurality of software, and determining the pathogenic genes through pathogenicity judgment; then, the WKH rat model is constructed by utilizing a genetic engineering CRISPR/Cas9 technology, the postnatal blood pressure of the mutant gene animal is continuously increased along with the age of the animal, and the systolic pressure of most offspring tail animals is more than 140mmHg.
The following is a further optimization or/and improvement of one of the above-mentioned technical solutions of the invention:
the mutant gene is the gene detection result of a special type of hypertension patient.
The experimental animal is selected from a mouse, a rat or a rabbit.
The specific gene point mutation F0 mouse is constructed by a CRISPR/Cas9 technology.
The specific gene mutation mouse is a descendant bred by the constructed F0 mouse.
The breeding condition of the mutant mice is an SPF animal breeding room, the room temperature is kept at 22 +/-2 ℃, the day and night period is 12 hours, and the mutant mice can be fed with food and water freely.
The invention provides a construction method of a human Cav1.3 hereditary hypertension rat model (Wang-Kang-Hui, WKH rat model). Firstly, discovering new sick Cav1.3 gene mutation sites of hypertension clinically, determining research target genes through literature retrieval and software prediction, constructing and screening a specific Cav1.3 gene mutation (WKH) rat model by utilizing a gene engineering CRISPR/Cas9 technology, comparing the model with a wild type WKH rat, and increasing the blood pressure of the screened specific single-gene mutation rat from 6 months of age, increasing the volume of glomeruli at 8 months of age, generating contraction, swelling the renal bursa, expanding the renal tubules, unclean lumen structures, thickening the walls of the renal arteriolar vessels and increasing fibrous tissues; cardiomyocyte enlargement; thickening secondary artery of mesentery, abnormal function of endothelium contraction and relaxation, etc.; the progress of these pathologies can be prevented or alleviated by therapeutic measures such as hypotensive drugs; when the Cav1.3 gene is further hybridized with WKH rats with two site variations, hypertension is completely developed in three months. The similarity protein structure search based on NCBI blasts shows that these Cav1.3 gene variation sites can be homologously modeled. In a word, the WKH rat model has specific humanized mutation, can provide a research tool for the effect of the gene in the development of hypertension, and provides a research model for continuously exploring pathogenesis related to hypertension and exploring a new target point of the antihypertensive effect.
Drawings
FIG. 1 shows the comparison of the heterozygous variation and homozygous variation of WKH gene in WKH wild type SD rats with the 7-32 week systolic blood pressure (SBP, 6 in each group): * P<0.05 and ** P<0.01: comparison of heterozygous mice with wild type mice, # P<0.05: homozygous mice were compared to heterozygous mice. A, a CACNA1D p.307 locus male mouse SBP time-varying trend chart; b: trend graph of time-dependent change of female mouse SBP of CACNA1D p.307 locus; c: trend graph of male mouse SBP of CACNA1D p.936 locus with time; d: trend plot of female mouse SBP at CACNA1D p.936 locus with time; e: a trend graph of the change of the SBP of the male mouse at the CACNA1D p.1516 locus along with time; f: trend graph of time-dependent change of SBP of female mouse with CACNA1D p.1516 locus; g: a trend graph of the change of the single gene heterozygous site variation of the CACNA1D p.307 site and the CACNA1D p.936 site and the change of the SBP of the male mouse combined variation of the two sites along with time; h: and (3) a time-dependent trend chart of the male mouse SBP of the single-site heterozygous variation of the CACNA1D p.307 site and the CACNA1D p.1516 site and the combined variation of the two sites.
FIG. 2 shows the results of the assay of 6 month WKY male rats (6 individuals in each group) plasma vasoconstrictor endothelin-1 with different genotypes of CACNA1D p.307: * : compared with wild mouseP<0.05。
FIG. 3 shows the change of kidney histomorphology of different genotypes of 8-month CACNA1D p.307 WKH rats.
FIG. 4 is a graph showing the change in kidney histomorphology for different genotypes of 8 month CACNA1D p.307 WKH rats.
FIG. 5 is a graph showing the change in kidney histomorphology for different genotypes of 8 month CACNA1D p.307 WKH rats.
FIG. 6 shows EH staining comparisons of mesenteric secondary arterioles of WKH rats of different genotypes (AA, AG and GG genotypes from left to right).
FIG. 7 shows the morphology and statistics of heart tissues of different genotypes of 8-month-old WKH rats.
FIG. 8 shows the three-dimensional structure analysis of protein after mutation of exon sites of CACNA1D gene and the action sites of different drugs on L-type calcium channel, in which A is the position of CACNA1D p.307 site, CACNA1D p.936 site and CACNA1D p.1516 site in L-type calcium channel cav1.3, B: action position of dihydropyridine calcium channel antagonist nifedipine in L-type calcium channel cav1.3, C: non-dihydropyridine nifedipine calcium channel antagonists act at the site of the L-type calcium channel cav 1.3.
Detailed Description
1. Animal preparation
The clean wild SD rat and CACNA1D gene point mutation rat are 24 (half of male and female), and the age of the rat is 4 weeks. Free diet, drinking water and life rhythm according to the circadian rhythm.
2. Animal grouping and model construction
The rat CACNA1D gene (GenBank accession number: NM-017298.1, ensembl. Contains 51 exons, the ATG initiation codon is located in exon 1, and the TAG termination codon is located in exon 51. And selecting the exon where the site screened in the early stage of the subject group is as a target site. Design gRNA targeting vector and donor oligonucleotide (with targeting sequence flanked by 130 bp homologous sequence): the site of mutation in the donor oligonucleotide will be introduced into this exon by homology directed repair. Silent mutations (from GAG to GAA or from GAC to GAT) will also be introduced to prevent homology directed repair of gRNA binding and re-cleavage of sequences. Cas9mRNA, gRNA produced by in vitro transcription, and donor oligonucleotide were co-injected into fertilized eggs to breed knock-in rats. These pups will be subjected to sequence analysis.
The model rat is characterized in that: to pairCacna1dP, D307G and p, R1516Q site mutation is carried out on the p.D307 and p.R1516 site of the No. 7 exon and the No. 35 exon respectively, and thenCacna1d G307G Homozygous mutant rat andCacna1d Q1516Q the homozygous mutant rat is hybridized to obtain DNA with two strandsCacna1d D307G/ R1516Q Two-site heterozygous mutant WKH rat model.
Grnas of the rat CACNA1D gene, donor oligonucleotides containing mutation sites and silent mutation (GAG to GAA) sites, and Cas9mRNA were co-injected into fertilized rat eggs to generate targeted knock-in offspring. F0 rats were subjected to sequence analysis and subsequently mated with wild type SD rats to produce F1-generation rats.
Co-injection of gRNA, donor oligonucleotide and Cas9mRNA of the rat CACNA1D gene into fertilized largeIn murine eggs to produce targeted knock-in offspring; identifying the F0 initial mouse by PCR, then carrying out sequencing identification, and finally hybridizing the F0 initial mouse to a wild rat to generate an F1 generation mouse; f1 generation mice are hybridized to respectively obtainCacna1d G307G Homozygous mutation andCacna1d Q1516Q homozygous mutant F2 rats, and hybridization of single-site homozygous mutant rats to obtain DNA fragments on both strandsCacna1d D307G/ R1516Q Two-site heterozygous mutant rat model.
The WKH rat model construction method comprises the following steps:
(1) RatCacna1dGene, geneBank accession No.: NM _017298.1, combination: ENSRNOG00000013147, located on rat chromosome 16;
(2) Fifty one exons have been identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 51; p.d307 and p.r1516 are located at exons 7 and 35, thus exons 7 and 35 are selected as target sites, respectively;
(3) gRNA targeting vectors and donor oligonucleotides were designed;
(4) The p.d307g, c.920atog and p.r1516q, c.4475 AGGtoCAG mutation sites in the donor oligonucleotides will be introduced into the corresponding exons by homology-directed repair; introduction of silent mutations (from GAG to GAA or from GAC to GAT) was required for the p.d307g (c.920atog) mutation to prevent gRNA binding and re-cleavage of the sequence following homology-directed repair;
(5) Mixing and injecting a cas9 sample mixing system into fertilized eggs, and transplanting to obtain an F0 generation rat;
(6) The positive F0 generation rats and the common SD rats are bred to obtain the compoundCacna1dGene knock-in positive F1-generation heterozygous SD rats;
(7) Hybridizing the F1 generation rat to obtain a single-site mutation homozygote F2 generation rat;
(8) Two single-site F2 generation homozygous rats were crossed to obtainCacna1d D307G/ R1516Q Two-site mutant rats.
Mating the F1 generations to obtain F2 generations, and then dividing the generations into a wild type group, a heterozygous subgroup and a homozygous subgroup according to different genotypes, wherein the specific grouping and modeling method comprises the following steps:
wild type group | Hybrid group | Group of homozygotes | |
Treatment of | Keeping room temperature at 22 + -2 deg.C for 12h day and night, and freely collecting and drinking water | Keeping room temperature at 22 + -2 deg.C for 12h day and night, and freely collecting and drinking water | Keeping room temperature at 22 + -2 deg.C for 12h day and night, and freely collecting and drinking water |
Time length (moon) | 8 | 8 | 8 |
And (3) measuring physiological and biochemical indexes: blood pressure was measured weekly from 50 days old, after 8 months of feeding, venous blood, content of endothelin-1 in serum was taken from each group of rats after fasting for 12 hours, heart and aorta were collected after sacrifice, and morphology of heart, kidney and aorta was examined.
The model is verified that SBP is larger than or equal to 140mmHg and is used as a standard for successful modeling of the hypertensive WKH rat.
Claims (6)
1. A WKH rat model construction method is characterized in that firstly, CRISPR/Cas9 technology is utilized to constructCacna1dA point mutation rat model, and then hybridizing two point mutation rats to obtain a double point mutation WKH rat model;
the rat model is characterized in that: to pairCacna1dP, D307G and p, R1516Q site mutation is carried out on the p.D307 and p.R1516 site of the No. 7 exon and the No. 35 exon respectively, and thenCacna1d G307G Homozygous mutant rat andCacna1d Q1516Q the homozygous mutant rat is hybridized to obtain DNA with two strandsCacna1d D307G/ R1516Q Two-site heterozygous mutant WKH rat model.
2. The method for constructing a WKH rat model according to claim 1, wherein: the rat model is selected from SD rats.
3. The method for constructing a WKH rat model according to claim 1 or 2, wherein: the method comprises the following two major steps, wherein the first step is particularly critical, and the specific steps are as follows:
(1) For ratsCacna1dGene, design of gene knock-in strategy, selection of knock-in region: p.D307 and p.R1516 are located in exons 7 and 35, respectively, and therefore exons 7 and 35 are selected as target sites, respectively;
(2) Construction by CRISPR/Cas9 techniqueCACNA1DGene single site mutant F0 rats;
(3) Hybridizing the F0 initial mouse and the wild type SD rat to respectively obtain the compoundCacna1d D307G AndCacna1d R1516Q site-mutated F1-generation mice;
(4) Hybridizing the F1 generation rat to obtain an F2 generation homozygote rat;
(5) Will be provided withCacna1d G307G Homozygous mutant rats andCacna1d Q1516Q homozygous mutant rat F2 mice were crossed to obtainCACNA1D D307G/R1516Q Double-site processAnd (5) changing into rats.
4. The WKH rat model construction method according to claim 3, characterized in that gRNA of rat CACNA1D gene, donor oligonucleotide and Cas9mRNA are co-injected into fertilized rat eggs to generate targeted knock-in offspring; identifying the F0 initial mouse by PCR, then carrying out sequencing identification, and finally hybridizing the F0 initial mouse to a wild rat to generate an F1 generation mouse; f1 generation mice are hybridized to respectively obtainCacna1d G307G Homozygous mutation andCacna1d Q1516Q homozygous mutant F2 rats, and hybridization of single-site homozygous mutant rats to obtain DNA fragments on both strandsCacna1d D307G/ R1516Q Two-site heterozygous mutant rat model.
5. The WKH rat model construction method as claimed in claim 4, comprising the steps of:
(1) Rat modelCacna1dGene, geneBank accession No.: NM-017298.1, ensembl: combining: ENSRNOG00000013147, located on rat chromosome 16;
(2) Fifty exons have been identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 51; p.D307 and p.R1516 are located at exons 7 and 35, respectively, thus exons 7 and 35 are selected as target sites, respectively;
(3) gRNA targeting vectors and donor oligonucleotides were designed;
(4) The p.d307g, c.920atog and p.r1516q, c.4475 AGGtoCAG mutation sites in the donor oligonucleotides will be introduced into the corresponding exons by homology-directed repair; for p.d307g, the c.920atog mutation requires introduction of silent mutations, from GAG to GAA or from GAC to GAT, to prevent gRNA binding and re-cleavage of the sequence after homology-directed repair;
(5) Mixing and injecting the cas9 mixed sample system into fertilized eggs, and transplanting to obtain F0 generation rats;
(6) The positive F0 generation rats and the common SD rats are bred to obtain the compoundCacna1dPositive F1 heterozygous for knock-insub-SD rats;
(7) Hybridizing the F1 generation rat to obtain a single-site mutation homozygote F2 generation rat;
(8) Two single-site F2 generation homozygous rats were crossed to obtainCacna1d D307G/ R1516Q Two-site mutant rats.
6. The WKH rat model construction method of claim 5, wherein the cas9 mixed sample system comprises sgRNA and cas9 mRNA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011326345.8A CN112522312B (en) | 2020-11-23 | 2020-11-23 | WKH rat model construction method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011326345.8A CN112522312B (en) | 2020-11-23 | 2020-11-23 | WKH rat model construction method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112522312A CN112522312A (en) | 2021-03-19 |
CN112522312B true CN112522312B (en) | 2022-10-04 |
Family
ID=74993070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011326345.8A Active CN112522312B (en) | 2020-11-23 | 2020-11-23 | WKH rat model construction method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112522312B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104293831A (en) * | 2014-09-28 | 2015-01-21 | 上海云舜生物技术有限公司 | Method for establishing hypertension mouse model and application of hypertension mouse model |
CN109662974A (en) * | 2018-11-01 | 2019-04-23 | 广西国际壮医医院 | A kind of method for building up of novel rat hypertension model and its application |
CN110885858A (en) * | 2019-11-01 | 2020-03-17 | 上海交通大学 | Construction method and application of Amy1 gene knockout mouse animal model |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7901885B2 (en) * | 2006-05-09 | 2011-03-08 | Dsm Ip Assets B.V. | Genes and markers in type 2 diabetes and obesity |
WO2014172470A2 (en) * | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal |
CN106929533B (en) * | 2017-03-10 | 2021-01-12 | 上海交通大学医学院附属新华医院 | Construction method and application of KARS gene point mutation mouse model |
CN107475300B (en) * | 2017-09-18 | 2020-04-21 | 上海市同济医院 | Construction method and application of Ifit3-eKO1 gene knockout mouse animal model |
CN111100877B (en) * | 2018-10-25 | 2022-05-10 | 北京市心肺血管疾病研究所 | Preparation method and application of hypertrophic cardiomyopathy mouse model |
CN111109199B (en) * | 2019-11-22 | 2022-02-18 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Slc12a9 gene knockout mouse model and establishment method and application thereof |
-
2020
- 2020-11-23 CN CN202011326345.8A patent/CN112522312B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104293831A (en) * | 2014-09-28 | 2015-01-21 | 上海云舜生物技术有限公司 | Method for establishing hypertension mouse model and application of hypertension mouse model |
CN109662974A (en) * | 2018-11-01 | 2019-04-23 | 广西国际壮医医院 | A kind of method for building up of novel rat hypertension model and its application |
CN110885858A (en) * | 2019-11-01 | 2020-03-17 | 上海交通大学 | Construction method and application of Amy1 gene knockout mouse animal model |
Also Published As
Publication number | Publication date |
---|---|
CN112522312A (en) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11234420B2 (en) | Method for constructing PD-1 gene modified humanized animal model and use thereof | |
CN108660161B (en) | Method for preparing chimeric gene-free knockout animal based on CRISPR/Cas9 technology | |
CN109628454B (en) | Construction method of zebra fish glycogen storage disease gys1 and gys2 gene mutant | |
CN104593418A (en) | Method for establishing humanized rat drug evaluation animal model | |
WO2018045727A1 (en) | Method for constructing an animal model for mucopolysaccharidosis type ii, and applications thereof | |
CN116218905B (en) | Construction and application of point mutation rat epilepsy model | |
CN108753837B (en) | Construction method of rabbit model with hyperlipidemia or atherosclerosis and sgRNA | |
WO2024103631A1 (en) | Transgenic mouse with ggc repeat expansion mutation in notch2nlc gene, construction method therefor, and use thereof | |
CN111485003A (en) | Construction method and application of retinal vascular disease model | |
CN112899311A (en) | Construction method and application of RS1-KO mouse model | |
CN105950654A (en) | A humanized transgenic animal | |
CN117604034A (en) | Method for preparing humanized TTR mice and application thereof | |
CN112522312B (en) | WKH rat model construction method | |
CN114457114B (en) | Construction method of animal model for conditional knockout of Fars2 gene | |
CN102450230A (en) | Mouse cataract model and construction method thereof | |
CN112626122B (en) | hKDR humanized mouse model and establishing method and application thereof | |
CN106399369B (en) | Build the method and targeting vector and kit in the mouse model of hippocampus regiospecificity knockout IKK α genes | |
CN112980881B (en) | Construction method and application of Arvcf gene knockout animal model | |
CN111705063B (en) | ASGR1 mutant gene and application thereof in preparation of mammal liver injury sensitive model | |
Schaefer et al. | Corrigendum and follow-up: Whole genome sequencing of multiple CRISPR-edited mouse lines suggests no excess mutations | |
CA2616258C (en) | Non-human animal model for cardiovascular disease characterized by a disrupted fibulin-4 gene | |
CN112063654A (en) | Construction method of point mutation thrombocytopenia mouse model | |
CN116334077B (en) | Construction method and application of airway epithelial cell SHP-1 gene specific knockout mouse model | |
CN114410691B (en) | Construction method and application of SLC35E1 gene knockout mouse animal model | |
CN114045290B (en) | Construction method and application of keratin gene modified mouse animal model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |